-+ 0.00%
-+ 0.00%
-+ 0.00%

Crism Therapeutics Treats First Patient in Mid-stage Glioblastoma Trial

MT Newswires·11/17/2026 04:26:49
Listen to the news
04:26 AM EST, 11/17/2026 (MT Newswires) -- Crism Therapeutics (CRTX.L) treated the first patient in its phase 2 clinical trial to treat glioblastoma patients with its irinotecan ChemoSeed implant. The UK clinical-stage drug delivery company said Tuesday that its study, which was conducted at the University Hospitals Birmingham NHS Foundation Trust, reported that the patient was clinically stable after the initial operations. The company added that the patient will now undergo post-operative clinical and imaging evaluations for the next steps of the trial.